Regeneron Pharmaceuticals presents a bullish thesis with a market capitalization of $70.94 billion, a trailing P/E ratio of 16.53, and trailing EPS of $40.94. The company delivered 19% year-over-year quarterly revenue growth on $14.92 billion in trailing twelve-month revenue, supported by strong operating margins of 20.7% and return on equity of 14.5%. These metrics position REGN favorably against peers in the biotechnology sector amid sustained demand for its innovative therapies.
Key catalysts include ongoing earnings momentum from flagship products like Eylea and Dupixent, with potential market expansion into new indications and international regions. Analyst consensus targets $819.18 per share, reflecting 16 strong buy ratings and 5 buy ratings, while forward P/E of 15.08 suggests continued earnings growth. Recent quarterly revenue expansion and a beta of 0.236 indicate resilience and growth potential through 2026.
Risks encompass regulatory hurdles for drug approvals, intense competition from other biotech firms, and macroeconomic headwinds such as inflation or reimbursement pressures. Mitigations include Regeneron's robust pipeline, high institutional ownership at 93.45%, and diversified revenue streams that have sustained 29.6% profit margins. The company’s low dividend yield of 0.53% and shares outstanding of 103.02 million further support a focused growth strategy over near-term payouts.
Get Deeper Analysis
Ask Theo anything about REGN — earnings, valuation, technicals, or portfolio fit.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Fundamental Snapshot
Revenue
14.9196B
EBITDA
4.3828B
Gross Profit
6.5475B
Operating Margin
20.7%
Profit Margin
29.6%
ROE
14.5%
Book Value
$308.32
Beta
0.236
52-Wk High
$818.9
52-Wk Low
$538.66
Avg Volume
700.762K
PEG Ratio
1.125
Trading Data
Open
$658.29
Previous Close
$651.91
Day Range
$654.05 – $667.5
Volume
701.789K
Shares Outstanding
103.022M
Analyst Target
$819.25
Frequently Asked Questions
What is Regeneron Pharmaceuticals' business model?
Regeneron operates as a biotechnology company focused on discovering, developing, and commercializing innovative medicines, primarily in ophthalmology, immunology, and oncology. It generates revenue through product sales, collaborations, and licensing, with trailing twelve-month revenue of $14.92 billion and a profit margin of 29.6%.
What are Regeneron's primary revenue sources?
The company's main revenue comes from sales of key drugs like Eylea and Dupixent, contributing to $14.92 billion in TTM revenue. Additional sources include collaboration agreements and royalties, supported by 19% year-over-year quarterly revenue growth.
What competitive advantages does REGN have?
Regeneron benefits from a strong R&D pipeline, proprietary VelociSuite technologies, and high barriers to entry in biotech. With 93.45% institutional ownership, a low beta of 0.236, and analyst target price of $819.18, it maintains a competitive edge in targeted therapies.
What are the key risks for REGN investors?
Key risks include regulatory approval delays, patent expirations, and competition in the biotech space. Macro factors like reimbursement changes could impact results, though mitigated by diversified products and a trailing P/E of 16.53 providing valuation support.
What is the growth outlook for REGN?
REGN shows solid growth potential with 19% YoY revenue growth, EPS of $40.94, and forward P/E of 15.08. Analysts rate it highly with a target of $819.18; next earnings momentum and pipeline advancements support continued expansion through 2026.
